Positive benefit-risk balance continues for glitazones – EMEA
- 7 Downloads
KeywordsRosiglitazone Pioglitazone Bone Fracture Product Characteristic Ischaemic Heart Disease
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
- 1.European Medicines Agency (EMEA).European Medicines Agency confirms positive benefit-risk balance for rosiglitazone and pioglitazone. Media Release: 18 Oct 2007. Available from: URL: http://www.emea.europa.eu
- 2.GlaxoSmirthKline.European Medicine Agency (EMEA) confirms positive Avandia benefit risk assessment. Media Release: 18 Oct 2007. Available from: URL: http://www.gsk.com
© Adis International limited or Adis Data Information BV 2007